Hoth Therapeutics Stock Forum

$Hoth Therapeutics (HOTH.US)$
 
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
On October 30, 2024, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq  Listing Rule 5550(a)(2) requires l...

$Hoth Therapeutics (HOTH.US)$ 5

$Hoth Therapeutics (HOTH.US)$ I believe we found the floor.

$Hoth Therapeutics (HOTH.US)$ fly 🚀🚀🚀🚀

$Hoth Therapeutics (HOTH.US)$
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment....

$Hoth Therapeutics (HOTH.US)$  coming up up up

$Hoth Therapeutics (HOTH.US)$ gone with the wind

$Hoth Therapeutics (HOTH.US)$
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
Hoth Therapeutics (NASDAQ: HOTH) has been granted a U.S. patent for its innovative Alzheimer's treatment, HT-ALZ. This breakthrough therapy targets the Substance P/Neurokinin-1 Receptor pathway, which is important in neuroinflammation, a key factor in Alzheimer's progression. Preclinical studies have shown promi...